CSPC ZhongQi Pharmaceutical Technology Co., Ltd. $1093.HK
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS27
PHASE 3 / 2-313
RECRUITING9
READOUTS ≤12 MONTHS7
READOUT SLIPPED >6 MO0%
Delay Index: of 9 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open CSPC ZhongQi Pharmaceutical Technology Co., Ltd. on the live radar map → 📅 $1093.HK readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| SKLB1028 Dose Escalation NCT05445154 |
P1/2 | Recruiting | Newly Diagnosed Acute Myeloid Leukemia (AML) | 58 | 2024-10-31 |
| Letrozole NCT06957379 |
P2 | Active, not recruiting | HR+/HER2- Advanced/Metastatic Breast Cancer | 78 | 2025-06 |
| DP303c NCT06313086 |
P3 | Recruiting | HER2-positive Breast Cancer | 442 | 2025-12 |
| DP303c NCT05901935 |
P3 | Not yet recruiting | HER2-positive Advanced Breast Cancer | 420 | 2026-01 |
| SYH9056 NCT06771245 |
P3 | Not yet recruiting | Mild-to-moderate Essential Hypertension | 606 | 2026-03-30 |
| Docetaxel for Injection (Albumin bound) NCT06492941 |
P3 | Not yet recruiting | Advanced Pancreatic Cancer | 142 | 2026-04-14 |
| Docetaxel for injection (Albumin-bound) NCT06296706 |
P3 | Recruiting | Gastric Cancer | 630 | 2026-06-01 |
| HB1801 NCT07116824 |
P2 | Not yet recruiting | HER2-positive Breast Cancer | 80 | 2026-07-15 |
| Sirolimus for Injection (Albumin-bound) NCT06929325 |
P3 | Not yet recruiting | HR+/HER2- Advanced/Metastatic Breast Cancer | 312 | 2026-10 |
| Hydroxocobalamin Chloride Injection NCT07163364 |
P3 | Not yet recruiting | Methylmalonic Acidemia (MMA) | 20 | 2026-10-08 |
| HB1801 NCT07083505 |
P2 | Not yet recruiting | Advanced Breast Cancer | 60 | 2026-10-11 |
| Glumetinib tablets NCT06525350 |
P2 | Not yet recruiting | Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression | 256 | 2026-12-25 |
| Docetaxel for Injection (Albumin-bound) NCT06136988 |
P1/2 | Not yet recruiting | Locally Advanced Unresectable Esophageal Squamous Carcinoma | 129 | 2027-04 |
| SYH2085 NCT07798193 |
P2 | Not yet recruiting | Influenza | 213 | 2027-04-30 |
| Glumetinib Tablets NCT06947291 |
P2 | Recruiting | Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors | 350 | 2027-04-30 |
| CM326 dose 1 NCT07418736 |
P2 | Recruiting | Chronic Obstructive Pulmonary Disease | 318 | 2027-07-01 |
| SYHX2008 injection NCT06505395 |
P2 | Recruiting | Gastrointestinal Neuroendocrine Pancreatic Tumor | 90 | 2027-08-01 |
| sirolimus (albumin-bound) NCT07241936 |
P1/2 | Recruiting | Advanced Solid Tumors | 444 | 2027-10-30 |
| Sirolimus for injection (Albumin-bound) NCT07684287 |
P2 | Not yet recruiting | Epithelioid Hemangioendothelioma | 40 | 2027-11-30 |
| Mitoxantrone Hydrochloride Liposome Injection NCT04668690 |
P3 | Active, not recruiting | Peripheral T Cell Lymphoma | 193 | 2027-12-30 |
| HB1801 NCT07805135 |
P3 | Not yet recruiting | HER2-Negative Advanced Breast Cancer | 430 | 2028-06-01 |
| HA131 NCT07282509 |
P1/2 | Not yet recruiting | Advanced Hepatocellular Carcinoma (HCC) | 116 | 2028-06-26 |
| Sirolimus for injection (albumin bound) NCT07165886 |
P2/3 | Recruiting | Gastroenteropancreatic Neuroendocrine Tumors | 298 | 2028-08-29 |
| SYH2051 NCT07911579 |
P1/2 | Not yet recruiting | Advanced Solid Tumors | 154 | 2028-12-30 |
| SYHX2008 NCT07623824 |
P3 | Not yet recruiting | Diagnosed With Acromegaly, Currently in the Active Stage of the Disease | 154 | 2029-07-31 |
| CM310 NCT06547333 |
P2/3 | Not yet recruiting | Chronic Obstructive Pulmonary Disease | 884 | 2032-04-29 |
| CM310 NCT05761028 |
P2/3 | Recruiting | Moderate to Severe Asthma | 600 | 2032-05 |